I
118THCONGRESS
1
STSESSION H. R. 6895
To amend the National Defense Authorization Act for Fiscal Year 2023
to extend Federal support for bioindustrial manufacturing processes to
include support for the manufacturing of certain pharmaceutical ingredi-
ents.
IN THE HOUSE OF REPRESENTATIVES
DECEMBER22, 2023
Ms. S
LOTKINintroduced the following bill; which was referred to the
Committee on Armed Services
A BILL
To amend the National Defense Authorization Act for Fiscal
Year 2023 to extend Federal support for bioindustrial
manufacturing processes to include support for the man-
ufacturing of certain pharmaceutical ingredients.
Be it enacted by the Senate and House of Representa-1
tives of the United States of America in Congress assembled, 2
SECTION 1. SHORT TITLE. 3
This Act may be cited as the ‘‘Defense Production 4
and Active Pharmaceutical Ingredients Act’’. 5
VerDate Sep 11 2014 00:30 Jan 09, 2024 Jkt 049200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H6895.IH H6895
kjohnson on DSK7ZCZBW3PROD with $$_JOB 2
•HR 6895 IH
SEC. 2. MODIFICATION OF SUPPORT FOR RESEARCH AND 1
DEVELOPMENT OF BIOINDUSTRIAL MANU-2
FACTURING PROCESSES. 3
Section 215(c)(1) of the James M. Inhofe National 4
Defense Authorization Act for Fiscal Year 2023 (Public 5
Law 117–263; 10 U.S.C. 4841 note) is amended by insert-6
ing ‘‘active pharmaceutical ingredients, key starting mate-7
rials for such ingredients,’’ after ‘‘commodity chemicals,’’. 8
Æ
VerDate Sep 11 2014 00:30 Jan 09, 2024 Jkt 049200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6301 E:\BILLS\H6895.IH H6895
kjohnson on DSK7ZCZBW3PROD with $$_JOB